Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Collplant Holdings ( (CLGN) ) is now available.
On March 26, 2026, CollPlant Biotechnologies reported its 2025 financial results and outlined a broad corporate update highlighting progress in aesthetics, 3D bioprinting, and regenerative implants. The company emphasized a development milestone in its AbbVie dermal-filler collaboration that triggered a $2 million payment in February 2025, expanded Vergenix STR distribution into North America through a U.S. logistics hub, and continued to strengthen its European network.
CollPlant advanced its rhCollagen-based 3D bioprinting portfolio with the February 2026 launch of BioFlex, a ready-to-print kit for high‑resolution Digital Light Processing, and showcased Mayo Clinic’s fully humanized 3D bioprinted skin model using its rhCollagen as an animal-testing alternative. A comparative study showed its Collink.3D BioInk outperformed Matrigel in structured tissue formation, underscoring its positioning in an animal‑free tissue engineering market estimated at about $100 million and growing at more than 10% annually.
In regenerative medicine, the company reported August 2024–2025 preclinical data on 200cc regenerative breast implants showing vascularization, rapid tissue ingrowth, maintained volume and mechanics, and no major complications at six months in one study arm. These implants are intended to regenerate breast tissue with reduced immune response risk, targeting both aesthetic and post‑mastectomy reconstruction needs amid rising concerns over traditional breast implant complications.
CollPlant also bolstered its intellectual property, securing a U.S. patent in February 2025 for its photocurable dermal filler candidate, and obtaining patent coverage for the same technology in South Korea, a key aesthetics market. In November 2025, it gained a second Japanese patent protecting its curable Collink.3D BioInk portfolio through 2038, reinforcing global IP protection around scalable, animal‑free, rhCollagen‑based BioInks that support high cell viability and consistent biofabrication.
The most recent analyst rating on (CLGN) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.
Spark’s Take on CLGN Stock
According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.
The score is held down primarily by weak financial performance—large ongoing losses, heavy cash burn, and a shrinking equity base despite some TTM revenue and gross margin improvement. Technicals provide partial support with a stronger short-term trend, but longer-term trend and momentum are mixed. Valuation remains unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on CLGN stock, click here.
More about Collplant Holdings
CollPlant Biotechnologies is an Israel-based regenerative and aesthetics medicine company that develops technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen). Its portfolio targets tissue regeneration, medical aesthetics, and 3D bioprinting applications, with growing focus on BioInk platforms and aesthetic fillers in key markets including the U.S., Europe, South Korea, and Japan.
Average Trading Volume: 79,195
Technical Sentiment Signal: Sell
Current Market Cap: $10.81M
For detailed information about CLGN stock, go to TipRanks’ Stock Analysis page.